van Dongen JJ - Search Results

1

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.

Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R, Falkenburg JH. Jedema I, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2004 Feb;18(2):316-25. doi: 10.1038/sj.leu.2403205. Leukemia. 2004. PMID: 14614514

2

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.

van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj. Leukemia. 2004 May;18(5):983-8. doi: 10.1038/sj.leu.2403350. Leukemia. 2004. PMID: 15029214 Free article.

3

Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype.

Staal FJ, de Ridder D, Szczepanski T, Schonewille T, van der Linden EC, van Wering ER, van der Velden VH, van Dongen JJ. Staal FJ, et al. Among authors: van der velden vh, van dongen jj, van der linden ec, van wering er. Leukemia. 2010 Mar;24(3):491-9. doi: 10.1038/leu.2009.286. Epub 2010 Jan 14. Leukemia. 2010. PMID: 20072147

4

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.

Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, Vossen JM, Versluys B, Egeler RM, van Tol MJ, Putter H, Révész T, van Dongen JJ, van der Velden VH, Schilham MW. Lankester AC, et al. Among authors: van der velden vh, van dongen jj, van tol mj, van wering er. Leukemia. 2010 Aug;24(8):1462-9. doi: 10.1038/leu.2010.133. Epub 2010 Jun 10. Leukemia. 2010. PMID: 20535148

5

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, van Dongen JJ, van der Velden VH. de Vries JF, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2012 Feb;26(2):255-64. doi: 10.1038/leu.2011.206. Epub 2011 Aug 26. Leukemia. 2012. PMID: 21869836

6

Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.

Boeckx N, Willemse MJ, Szczepanski T, van der Velden VH, Langerak AW, Vandekerckhove P, van Dongen JJ. Boeckx N, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2002 Mar;16(3):368-75. doi: 10.1038/sj.leu.2402387. Leukemia. 2002. PMID: 11896540

7

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.

van der Velden VH, Willemse MJ, van der Schoot CE, Hählen K, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van der schoot ce, van wering er. Leukemia. 2002 May;16(5):928-36. doi: 10.1038/sj.leu.2402475. Leukemia. 2002. PMID: 11986956

8

T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis.

van der Velden VH, Wijkhuijs JM, Jacobs DC, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. Leukemia. 2002 Jul;16(7):1372-80. doi: 10.1038/sj.leu.2402515. Leukemia. 2002. PMID: 12094263

9

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.

van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hählen K, Kamps WA, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. Leukemia. 2002 Aug;16(8):1432-6. doi: 10.1038/sj.leu.2402636. Leukemia. 2002. PMID: 12145681

10

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj. Leukemia. 2003 Jun;17(6):1013-34. doi: 10.1038/sj.leu.2402922. Leukemia. 2003. PMID: 12764363 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

581 results

Search Page